INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352 ...
A post-hoc analysis from OTEMTO ® 1&2 indicates that Spiolto ® Respimat ® provides significant quality of life improvements over Spiriva ® Respimat ® (tiotropium) or placebo, right from the initial ...
Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A posthoc analysis from OTEMTO® 1&2 indicates that ...
Spiolto® Respimat® is built on tiotropium, the active ingredient in Spiriva®, enhanced by olodaterol Spiolto® Respimat® provides significant improvements in lung function, COPD symptoms, quality of ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Spiolto Respimat contains the active ingredients tiotropium (as ...
GlaxoSmithKline and Innoviva say their combination lung therapy Anoro Ellipta has come out on top in a trial pitting its effectiveness in improving lung function against that of Boehringer Ingelheim’s ...
Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A post-hoc analysis from OTEMTO ® 1&2 indicates that ...
Boehringer Ingelheim today announced the presentation of several new post-hoc analyses from the TONADO® 1&2 and OTEMTO® 1&2 studies at the American College of CHEST Physicians Annual Meeting in ...
Further data from the 1,600 patient OTEMTO® trials show Spiolto® Respimat® provides: clinically meaningful improvements in breathlessness compared to placebo (measured by a 1.62 point improvement in ...
OTEMTO® trials show Spiolto® Respimat® provides clinically meaningful >4 point reduction in SGRQ score compared to placebo1These results demonstrate that Spiolto® Respimat® can bring noticeable ...
Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto ® Respimat ...
Spiolto ® Respimat ® is built on tiotropium, the active ingredient in Spiriva ® – the world’s most prescribed COPD maintenance treatment with over 40 million patient years of real life experience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results